Peptides DB
Research-centric peptide and protocol reference hub
Study 4 of 6Lypressin literatureThe Libyan journal of medicine · Meta-analysis2026

Prevalence and impact of hyponatremia in chronic obstructive pulmonary disease. A systematic review and meta-analysis.

Hyponatremia is prevalent in COPD and AECOPD patients, with rates of 14% and 19% respectively, but significant variability among studies suggests careful interpretation of these findings.

Read at The Libyan journal of medicineAdd to compare

Where it sits

this study against the rest of the lypressin corpus
0
Preclinical
4
Observational
0
Open-label
1
Randomised
1
Reviews · this one

Summary and findings

This systematic review and meta-analysis measured the prevalence of hyponatremia in patients with chronic obstructive pulmonary disease (COPD) and acute exacerbations of chronic obstructive pulmonary disease (AECOPD). The analysis included 11 studies, reporting a pooled prevalence of 14% in COPD patients and 19% in AECOPD patients. No treatment claims are made regarding the impact of hyponatremia on these conditions.

How much of this paper we could read: full text read (0.80). We had a clear abstract, so the summary below closely tracks the paper. What this means →
Pooled prevalence of hyponatremia among COPD patients was 14% (95% CI: 4%-28%).2026

Abstract

The authors’ words, as The Libyan journal of medicine supplied them

Hyponatremia has been found to be associated with chronic obstructive pulmonary disease (COPD) and acute exacerbations of chronic obstructive pulmonary disease (AECOPD). However, there is a lack of systematic evidence on the prevalence and impact of hyponatremia in COPD and AECOPD patients. We performed a systematic search on three major databases for articles published on or before 31 July 2025. We included all the studies reporting the prevalence or number of hyponatremia cases in COPD patients (stable and exacerbation) aged 18 years and above. Pooled prevalence was calculated by a random effects model using RStudio. The Joanna Briggs Institute (JBI) tool was used for quality evaluation of the included studies. In this systematic review and meta-analysis, we included 11 studies out of 284 studies retrieved in the initial search. Of these 11 studies, three were COPD studies, and eight were AECOPD studies. The pooled prevalence of hyponatremia among COPD patients was 14% (95% CI: 4%-28%), with significant heterogeneity (<i>I</i>² = 98.3%, <i>p </i>< 0.0001). The pooled prevalence of hyponatremia in AECOPD patients was 19% (95% CI: 9%-32%), with significant heterogeneity (<i>I</i>² = 98.8%, <i>p </i>< 0.0001). Most of the studies showed that hyponatremia was not associated with mortality as an outcome of AECOPD. This study found a high prevalence of hyponatremia in both COPD and AECOPD patients; however, substantial heterogeneity (<i>I</i>² > 98%) necessitates cautious interpretation of pooled estimates. Future studies with standardized diagnostic criteria and larger sample sizes are needed to establish more precise prevalence rates.

Background

This paper addresses the prevalence and impact of hyponatremia in patients with chronic obstructive pulmonary disease (COPD) and acute exacerbations of COPD (AECOPD). Previous literature has suggested an association between hyponatremia and COPD, but systematic evidence was lacking. This study is significant as it aggregates data from multiple studies to provide a clearer picture of hyponatremia's prevalence in these patient populations.

Methods

The study conducted a systematic search across three major databases for articles published until July 31, 2025. It included studies reporting the prevalence or number of hyponatremia cases in COPD patients aged 18 years and older. A total of 11 studies were included in the analysis, with a focus on pooled prevalence calculated using a random effects model.

Results

The primary endpoint revealed that the pooled prevalence of hyponatremia among COPD patients was 14% (95% CI: 4%-28%), indicating a notable occurrence of this condition. For AECOPD patients, the pooled prevalence was found to be 19% (95% CI: 9%-32%). Both findings exhibited significant heterogeneity, with I² values of 98.3% and 98.8% respectively, and p-values less than 0.0001.

Interpretation

The findings suggest a high prevalence of hyponatremia in both COPD and AECOPD populations, which aligns with some prior studies but also raises concerns due to the significant heterogeneity observed. While the prevalence rates are statistically significant, the clinical relevance may be limited given the high variability among studies and the lack of consistent association with mortality outcomes. These confounds necessitate caution in applying these findings to clinical practice.

Key findings

  • Pooled prevalence of hyponatremia among COPD patients was 14% (95% CI: 4%-28%), n=11 studies.
  • Pooled prevalence of hyponatremia in AECOPD patients was 19% (95% CI: 9%-32%), n=11 studies.
  • Significant heterogeneity in COPD studies with I² = 98.3%, p<0.0001.
  • Significant heterogeneity in AECOPD studies with I² = 98.8%, p<0.0001.
  • Most studies indicated hyponatremia was not associated with mortality in AECOPD.

Limitations

  • Substantial heterogeneity in prevalence estimates (I² > 98%).
  • Limited to studies published before July 31, 2025.
  • Most studies did not find an association between hyponatremia and mortality.
  • Small sample sizes in individual studies may affect reliability.
  • Potential publication bias not addressed.

Elsewhere in the Lypressin corpus

DRandomized controlled trial of desmopressin plus terlipressin vs. terlipressin alone for the treatment of acute variceal hemorrhage in cirrhotic patients: a multicenter, double-blind study. New Italian Endoscopic Club.Hepatology (Baltimore, Md.) · 1993BMedFusion-gP-AKI: development and multicenter validation of a machine learning fusion model for early prediction of KDIGO stage 3 acute kidney injury in critically ill traumatic cervicothoracic spinal cord injury patients.Renal failure · 2026 · n=188 · AUC of 0.938 for model performance.HumanBPrognostic value of stress hyperglycemia ratio in critically Ill patients with acute kidney injury: a machine learning-driven retrospective cohort analysis.Health information science and systems · 2023 · n=5555 · HR > 1, p < 0.01 for both 30-day and 90-day mortality.HumanCTreatment with low-dose bicistronic immunotherapy mitigates parasite persistence and improves serological and cardiac outcomes in adult mice infected with &lt;i&gt;Trypanosoma cruzi&lt;/i&gt;: comparative analysis with benznidazole.Emerging microbes & infections · 2026 · Treatment with BCV, BCVR or BZN achieved >95% control of parasite burden.AnimalBElevated atherogenic index of plasma is associated with severe acute kidney injury in critically ill patients with cardiovascular disease - a MIMIC-IV analysis with external validation in the eICU-CRD database.Renal failure · 2026 · n=5872 · Adjusted OR for high AIP associated with stage 3 AKI was 1.35 (95% CI: 1.11-1.64)Human